Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Probably statements on Syria nerve gas along with N Korea. Administration has promised action.
Looking pretty good today. Just a few pennies getting attention and this is one of them. I really like the stem cell enhancement story. If it works as indicated it would revolutionize critical medicine even more than medical MJ IMO. They seem to have critical patents that could make them the leader in a unique space.
I added another 50,000 shares this am. This could be a big winner with just a few in demand apps.
I wouldn't want to be short here. This could be a ball breaker for those folks.
Getting those audited statements are a big deal.
I earlier recommended OWC$ and he bought a big position at 6 cents and sold at a huge profit. Accumulation of RJDG can be a slow process here in order not to run it, but he got 400,000 shares today. Slow acquisition is not a bad move and you have proved it with your monster position at a low average cost.
There should be a nice solid base somewhere around here, but who cares? Anything discounted from here is pure profit and very soon.
My CPA finally picked up a nice sized chunk today. Audited statements are crucial to investor interest and it's on the way. I would never recommend the stock to him otherwise.
ENDV closing up nicely today (+60%)
IMLFF sure getting volume/price attention in MJ medical play, might be worth a look.
The CEO of RJDG company has also gained control of SWRM and cut OS in half to 50 million OS and he owns 5 million shares of the OS. The company also generated $500,000 in past quarter and reduced outstanding debt by $500,000 or so.
Meanwhile this stock has come down from $200 million MC so if they can execute in the market development of Apps it could be a huge winner when you consider MC now at $500,000 plus. Meanwhile one big App JV could dramatically increase the stock price.
Do your DD and evaluate your risk JMHO
Loaded ENVD at .035 ave. and holding for long term. Also been accumulating RJDG at ave. .013 and currently .0189 they just announced audit and potential up-list could be headed our way. In focus is their acquisition of a payment platform just approved for some significant healthcare provider revenue. Estimated initial market penetration at $30 Million revenue at 60% EBIDA. Rollout underway starting now. No promises as usual but evaluate the stock based risk reward management. Last OS revealed was 176 million and about 50 million + float. This little company is already profitable. It appears RJDG could earn as much as current share price in 2017, but no promises and certainly do your DD before investing. JMHO
Rounded up to 1 million shares this morning. Long term hold, one great app would explode the price here.
Greekgal has insider information on RJDG plus intends to act on it, report her to the SEC immediately.
ENDV closed up 54% at .057....Nice.
Let them eat Greek Salad instead of RJDG shares.
ENDV sure an interesting electrical biomedical story and some big players involved in that field. They have some interesting patents and special features of their technology that could make them an acquisition candidate. Trading at 4.5 cents and about 150 million OS
You are right about the drug candidates, but my recollection is that fully diluted there is about 45 million OS so $225 million MC at $5.00..
Looks like big breakout today.
The new health care proposal is looking for cost cutting/efficiency at all levels. The software platform here could grab some serious attention with TPA's and providers.
I am way overweight on biotech stocks and Trump is looking for serious cuts on Pharmaceutical Drug costs. That is why I like holding RJDG because they appear to be in the right place at the right time with their platform and an explosive opportunity for growth at high margins.
I hear you, we all operate in our comfort zone.
I am going to wait patiently for another drop in price by MM's to load a few 100 thousand more shares. Got a nice position so content to watch and wait.
Added 430,000 when they dropped it down
Picked up a few more shares.
This technology appears to change the viability and resiliency of organ and or stem cell transplants.
This is a game changer if it works as advertised. There would essentially be nothing else on the horizon that could address this need. OS is peanuts if that is the case.
A quick ramp up in software revenue could easily cover it.
4.8% of outstanding shares that was posted. It must be larger than what was posted.
That's only about 8 million shares dilution.
I rounded up to 3.9 million shares today. Seems like a no brainer here. What if they get $100 million software revenue in the next couple years? Seems possible to me when they project initial potential software revenue of $30 million and they have millions of contacts and it appears they only have 90 customers with these projections. I could be wrong but there is serious upside here when there are 50% net margins in their software business.
Bought another 1 million shares in total today
Added another 450,000 shares today
Added 1/2 million this am.
I added 250,000 as well.
The con game from shorts is on full attack. They however have so little class that the attack will do zip to get VDRM solid longs to sell their shares.
Rain, our investment in PKTX sure is looking great. Phase 1/2 clinical trials could revolutionize all organ transplants in addition to islet transplants and change treatment for uncontrolled type 1 diabetes.
In addition UBC starting experimentation for stem cell transplants is another huge opportunity.
The company is so far under the radar with such advanced technology.
You are right, it is a pretty rare to see confidential treatment exemption like this. Hopefully we see more news soon.
Rain brought NMUS to my attention awhile back. It is hard to figure out why this stock is so overlooked.
Adjust that revenue number to a wholesale price, but then anticipate how quickly off shore sales open up. Difficult to figure out what may happen.
I know my figures don't add up, just trying to understand the reality of what we think we know about OS and float.
The other negative action by antibiotics is on the micro-biome in the gut from overuse of oral antibiotics. Look up the affects of deadly C-dif from long term use so a simple topical used here eliminates the risk.
I don't pretend to be a expert pharmacy back ground person but I was trained as an employee in the marketing divisions on what the oral targeting/base results principles were when I was there. Obviously the targeting/results may be vastly different but the oral degradation hasn't been solved along with noted side affects. (read the labels on medication)
Exactly, you eliminate the stomach irritation and liver toxicity experienced by many patients on other medications.
I worked with Pfizer and Roche in my youth (79 now)and one of the key parameters was degradation of an oral pill to get the decided affects without causing harm (side affects). This solves that issue and possibly allows the action of the (mini CBD's) to activated by the delivery system.
Just my thought process and hopefully not considered a pump to trade. I own a nice position and here for the Diabetic Ulcer benefit. Example my 89 year old brother broke his ankle, got an infection after surgery and it took one full year of nursing assistance with bandages/wraps/consultations to finally get it somewhat healed. What a huge expense and patient trauma for something so simple.